Results 211 to 220 of about 126,669 (262)

Recovery from post-COVID-19 vaccination biliary ductopenia and multiorgan inflammation: A case with insight from angiotensin II type 1 receptor antibody- mediated injury

, 2023
Chang A, Jeng Y, Ho C, Lee P.
europepmc   +1 more source

Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial

ESC Heart Failure, EarlyView.
Central Illustration caption: This analysis of vericiguat's treatment effect revealed no inter‐geographic region heterogeneity for the primary composite endpoint (time to HF‐related hospitalization or cardiovascular (CV) death or its components) (Left Panel).
Cynthia M. Westerhout, Wendimagegn Alemayehu, Alain Cohen‐Solal, Carolyn S. P. Lam, Justin A. Ezekowitz, Stefano Corda, Ciaran J. McMullan, Christopher M. O'Connor, Paul W. Armstrong, for the VICTORIA Study Group   +9 more
wiley   +1 more source

Influence of Angiotensin II Type 1-Receptor Antagonist CV11974 on Infarct Size and Adjacent Regional Function After Ischemia-Reperfusion in Dogs

, 2002
Hironori Miyoshi, Yasuo Takayama, Shuji Kitashiro, Toshio Izuoka, Daiki Saito, Yusuke Imuro, Jun Mimura, Satoshi Yamamoto, Mari Tokioka, Toshiji Iwasaka   +9 more
openalex   +1 more source

Percutaneous endocardial alginate–hydrogel injection in the treatment of heart failure: First‐in‐human study

ESC Heart Failure, EarlyView.
Using EndoWings™ and XDROP™, we developed a percutaneous minimally invasive technique for sequential circumferential alginate hydrogel injection into LV free mid‐wall. This human study assessed its safety/feasibility in HFrEF patients, with personalised biomechanical models.
Bo Wang, Shuo Wang, Chao Gao, D. Scott Lim, Rutao Wang, Xin Meng, Ying Liu, Cun‐jun Zhu, Yoshinobu Onuma, Yunbing Wang, Patrick W.J.C. Serruys, Runlin Gao, Randall J. Lee, Ling Tao   +13 more
wiley   +1 more source

Nurse‐coordinated multidisciplinary comprehensive heart failure management programme: A propensity‐matched trial

ESC Heart Failure, EarlyView.
Abstract Aims Despite therapeutic advancements, the prognosis of heart failure (HF) remains poor, with high rates of mortality and readmission, particularly following a HF exacerbation. This study aimed to evaluate the effects of a nurse‐coordinated multidisciplinary comprehensive HF management programme on HF patients.
Cecilia Miu‐Ching Chan, Polly Wai‐Chi Li, Derek Pok‐Him Lee, Esmond Yan‐Hang Fong, Ivy Sin‐Yee Ng, Samantha Ki‐Man Chiu, Clara Woon‐Shan Fok, Frederick Kin‐Wa Li, Shirley Ka‐Wai Lee, Karen K. Y. Ho, Wilson Y. S. Leung, Cathy Cheuk‐Sum Chan, Cindy Yiu‐Ning Tsang, Michael Kang‐Yin Lee   +13 more
wiley   +1 more source

Activating types 1 and 2 angiotensin II receptors modulate the hypertrophic differentiation of chondrocytes

, 2014
一郎 墳本
openalex   +1 more source

Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA‐MI

ESC Heart Failure, EarlyView.
We investigated cardiometabolic outcomes in patients treated with dapagliflozin 10 mg once daily or placebo after acute myocardial infarction according to LVEF at randomisation in the registry‐based, randomised DAPA‐MI trial. Regardless of baseline LVEF, dapagliflozin resulted in significant cardiometabolic benefits versus placebo, suggesting that ...
David Erlinge, Stefan James, John Deanfield, Niclas Eriksson, Mark de Belder, Monér Alchay, David Austin, Daniel A. Jones, Annica Ravn‐Fischer, Sofia Sederholm Lawesson, Nikunj Shah, Julian W. Strange, Karolina Szummer, Wilhelm Ridderstråle, Ehsan Parvaresh Rizi, Anna Maria Langkilde, Peter A. Johansson, Darren K. McGuire, Jonas Oldgren, Robert F. Storey   +19 more
wiley   +1 more source

Novel mutation associated with non‐compaction ventricular myocardium: A case report

ESC Heart Failure, EarlyView.
Yan Li, Xi Wang, Saiyong Chen, Chun Wu, Fushi Piao   +4 more
wiley   +1 more source

Finerenone in diabetic chronic kidney disease—Real‐world insights including patients with HFpEF or HFmrEF

ESC Heart Failure, EarlyView.
Abstract Purpose Finerenone, a highly selective non‐steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD). Finerenone reduced the composite endpoint of heart failure events and cardiovascular death in patients with heart ...
Kristian Hellenkamp, Sophia Kaebe, Miroslava Valentova, Stephan von Haehling, Fani Delistefani, Katja Gollisch, Dirk Raddatz, Ann‐Kathrin Schäfer, Michael J. Koziolek, Manuel Wallbach   +9 more
wiley   +1 more source